Peritoneal defense using icodextrin or glucose for daytime dwell in CCPD patients

Peritoneal Dialysis International

Volumn 19, Issue 4, 1999, Pages 334-342

  Posthuma, Nynke ^a   Ter Wee, Pieter M ^a   Donker, Ab J M ^a   Dekker, Hubertha A Th ^b   Oe, Po L ^a   Verbrugh, Henri A ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Biocompatibility; CCPD; Cytokine; Glucose; Icodextrin; Macrophage; Opsonic capacity; Peritoneal defense; Peritonitis; Phagocytosis

Indexed keywords

CYTOKINE; GLUCOSE; ICODEXTRIN;

ADULT; AEROBIC METABOLISM; ARTICLE; CELL METABOLISM; CHRONIC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INFECTION; LEUKOCYTE COUNT; MALE; MESOTHELIUM CELL; OPSONIZATION; PERITONEAL DIALYSIS; PERITONEUM MACROPHAGE; PERITONITIS; PHAGOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0033429178     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901900409     Document Type: Article

References (26)

1. Jörres A, Gahl GM, Frei U. In vitro studies on the effect of dialysis solutions on peritoneal leukocytes. Perit Dial Int 1995; 15(7, Suppl):S41-5.
2. de Fijter CWH, Verbrugh HA, Peters EDJ, Oe PL, van der Meulen J, Verhoef J, et al. In vivo exposure to the currently available peritoneal dialysis fluids decreases the function of peritoneal macrophages in CAPD. Clin Nephrol 1993; 39:75-80.
3. Douvdevani A, Rapoport J, Konforti A, Zlotnik M, Chaimovitz C. The effect of peritoneal dialysis fluid on the release of IL-1 beta and TNF alpha by macrophages/ monocytes. Perit Dial Int 1993; 13:112-17.
4. Rooney OB, Dodd PD, Gokal R, Walker MG. Dialysis fluid cytotoxicity and inhibition of host defence in cultured human mesothelial cells are neutralized rapidly with incubation in the peritoneum. Nephrol Dial Transplant 1996; 11:2472-7.
5. Alobaidi HM, Coles GA, Davies M, Lloyd D. Host defence in continuous ambulatory peritoneal dialysis: the effect of the dialysate on phagocyte function. Nephrol Dial Transplant 1986; 1:16-21.
6. Mahiout A, Matata BM, Brunkhorst R. Effect of glucose and pyruvate in acidic and non-acidic peritoneal dialysis fluids on leukocytes cell functions. Kidney Int 1997; 51:860-7.
7. Fischer FP, Schenk U, Kiefer T, Hubel E, Thomas S, Yatzidis H, et al. In vitro effects of bicarbonate-versus lactate-buffered continuous ambulatory peritoneal dialysis fluids on peritoneal macrophage function. Am J Kidney Dis 1995; 26:924-33.
8. Vanholder R, Lameire N, Waterloos MA, Van Landschoot N, De Smet R, Vogeleere P, et al. Disturbed host defense in peritoneal cavity during CAPD: characterization of responsible factors in dwell fluid. Kidney Int 1996; 50:643-52.
9. Alsop RM. History, chemical, and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14(Suppl 2):S5-12.
10. Mistry CD, Gokal R, Peers EM. A randomized multicentre clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in continuous ambulatory peritoneal dialysis: a six month study. Kidney Int 1994; 46:496-503.
11. Posthuma N, ter Wee PM, Verbrugh HA, Oe PL, Peers E, Sayers J, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550-3.
12. de Fijter CWH, Verbrugh HA, Oe PL, Heezius E, Donker AJM, Verhoef J, et al. Biocompatibility of a glucosepolymer-containing peritoneal dialysis fluid. Am J Kidney Dis 1993; 21:411-18.
13. Brulez HF, Moncasi EP, Posthuma N, Choy K, ter Wee PM. The efficacy of intraperitoneally administered gentamicin and rifampin as initial treatment of peritoneal dialysis-related peritonitis. In: Khanna R, ed. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Publications, 1995; 11:182-6.
14. Posthuma N, ter Wee PM, Donker AJM, Peers EM, Oe PL, Verbrugh HA. Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 1998; 13:2341-4.
15. Verbrugh HA, Hoidal JR, Nguyen BY, Verhoef J, Quie PG, Peterson PK. Human alveolar macrophage cytophilic immunoglobulin G-mediated phagocytosis of protein A-positive staphylococci. J Clin Invest 1982; 69:63-74.
16. Peterson PK, Verhoef J, Schmeling D, Quie PG. Kinetics of phagocytosis and bacterial killing by human polymorphonuclear leukocytes and monocytes. J Infect Dis 1977; 136:502-9.
17. Verbrugh HA, Peters R, Peterson PK, Verhoef J. Phagocytosis and killing of staphylococci by human polymorphonuclear and mononuclear leucocytes. J Clin Pathol 1978; 31:539-45.
18. Bjerknes R, Bassoe CF, Sjursen H, Laerum OD, Solberg CO. Flow cytome try for the study of phagocyte functions. Rev Infect Dis 1989; 11:16-33.
19. van Strijp JA, van Kessel K, van der Tol ME, Fluit AC, Snippe H, Verhoef J. Phagocytosis of herpes simplex virus by human granulocytes and monocytes. Arch Virol 1989; 104:287-98.
20. Verbrugh HA, Keane WF, Hoidal JR, Freiberg MR, Elliott G, Peterson PK. Peritoneal macrophages and opsonins: antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis 1983; 147:1018-29.
21. Mills EL, Rholl KS, Quie PG. Luminol-amplified chemiluminescence: a sensitive method for detecting the carrier state in chronic granulomatous disease. J Clin Microbiol 1980; 12:52-6.
22. van Bronswijk H, Verbrugh HA, Heezius H, van der Meulen J, Oe PL, Verhoef J. Dialysis fluids and local host resistance in patients on continuous ambulatory peritoneal dialysis. Eur J Clin Microbiol Infect Dis 1988; 7:368-73.
23. Timmerman CP, Mattsson E, Martinez - Martinez L, de Graaf L, van Strijp J, Verbrugh HA, et al. Induction of release of tumor necrosis factor from human monocytes by staphylococci and staphylococcal peptidoglycans. Infect Immun 1993; 61:4167-72.
24. Brulez HF, Verbrugh HA. First-line defense mechanisms in the peritoneal cavity during peritoneal dialysis. Perit Dial Int 1995; 15(7, Suppl):S24-33.
25. Betjes MG, Tuk CW, Struijk DG, Krediet RT, Arisz L, Hoefsmit EC, et al. Immuno-effector characteristics of peritoneal cells during CAPD treatment: a longitudinal study. Kidney Int 1993; 43:641-8.
26. Betjes MG, Bos HJ, Krediet RT, Arisz L. The mesothelial cells in CAPD effluent and their relation to peritonitis incidence. Perit Dial Int 1991; 11:22-6.